Analyst Price Target is $27.00
▲ +4.41% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lantheus in the last 3 months. The average price target is $27.00, with a high forecast of $34.00 and a low forecast of $20.00. The average price target represents a 4.41% upside from the last price of $25.86.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Lantheus. This Buy consensus rating has held steady for over two years.
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes, and assist clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment operations offers direct distribution in Canada and Puerto Rico; third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America; and EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.